Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746019 | 0.87 | CA1 (0.36) | CA1CA2CA12CA9P4HB | |
| SCHEMBL23745978 | 0.86 | CA1 (0.43) | CA1CA2CA12CA9P4HB | |
| SCHEMBL23745974 | 0.82 | CD74 (0.35) | — | |
| SCHEMBL30633644 | 0.82 | CD74 (0.35) | — | |
| SCHEMBL23745931 | 0.81 | MAOB (0.36) | CA1CA2CA12CA9PDK2 | |
| SCHEMBL28549912 | 0.79 | HSD11B1 (0.46) | CA1CA2CA12CA9 | |
| SCHEMBL21693455 | 0.79 | HSD11B1 (0.46) | CA1CA2CA12CA9 | |
| SCHEMBL23745906 | 0.78 | STAT3 (0.39) | CA1CA2CA12CA9F2 | |
| SCHEMBL23746004 | 0.75 | CA1 (0.48) | CA1CA2CA12CA9EGFR | |
| SCHEMBL21693479 | 0.74 | CA1 (0.40) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | MAOB, LOX, LPO | CA1 1688/4885CA2 1164/4885CA12 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.